Conformational selection of vasopressin upon V\textsubscript{1a} receptor binding

Kateryna Che\textsuperscript{a}, Markus Muttenthaler\textsuperscript{a,b}, Dennis Kurzbach\textsuperscript{a,*}

\textsuperscript{a}University Vienna, Faculty of Chemistry, Institute of Biological Chemistry, Währinger Str. 38, A-1090 Vienna, Austria
\textsuperscript{b}The University of Queensland, Institute for Molecular Bioscience, 306 Carmody Rd, 4072 St Lucia, Brisbane, Queensland, Australia

A R T I C L E   I N F O

Article history:
Received 29 June 2021
Received in revised form 14 October 2021
Accepted 14 October 2021
Available online 18 October 2021

Keywords:
Molecular recognition
Conformational selection
Molecular dynamic simulations
In silico docking
NMR spectroscopy
Vasopressin
V\textsubscript{1a} receptor

A B S T R A C T

The neuropeptide vasopressin (VP) and its three G protein-coupled receptors (V\textsubscript{1aR}, V\textsubscript{1bR}, and V\textsubscript{2R}) are of high interest in a wide array of drug discovery programs. V\textsubscript{1aR} is of particular importance due to its cardiovascular functions and diverse roles in the central nervous system. The structure–activity relationships underpinning ligand-receptor interactions remain however largely unclear, hindering rational drug design. This is not least due to the high structural flexibility of VP in its free as well as receptor-bound states. In this work, we developed a novel approach to reveal features of conformational selectivity upon VP-V\textsubscript{1aR} complex formation. We employed virtual screening strategies to probe VP's conformational space for transiently adopted structures that favor binding to V\textsubscript{1aR}. To this end, we dissected the VP conformational space into three sub-ensembles, each containing distinct structural sets for VP's three-residue C-terminal tail. We validated the computational results with experimental nuclear magnetic resonance (NMR) data and docked each sub-ensemble to V\textsubscript{1aR}. We observed that the conformation of VP's three-residue tail significantly modulated the complex dissociation constants. Solvent-exposed and proline trans-configured VP tail conformations bound to the receptor with three-fold enhanced affinities compared to compacted or cis-configured conformations. The solvent-exposed and more flexible structures facilitated unique interaction patterns between VP and V\textsubscript{1aR} transmembrane helices 3, 4, and 6 which led to high binding energies. The presented “virtual conformational space screening” approach, integrated with NMR spectroscopy, thus enabled identification and characterization of a conformational selection-type complex formation mechanism that confers novel perspectives on targeting the VP-V\textsubscript{1aR} interactions at the level of the encounter complex – an aspect that opens novel research avenues for understanding the functionality of the evolutionary selected conformational properties of VP, as well as guidance for ligand design strategies to provide more potent and selective VP analogues.

© 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Vasopressin (VP) is a highly conserved neuropeptide that acts via three class A (rhodopsin like) G protein-coupled receptors (GPCRs) [1]: vascular (V\textsubscript{1aR}) [2], pituitary (V\textsubscript{1bR}) [3], and renal (V\textsubscript{2R}) [4,5]. VP regulates several vital body functions including water balance and salt homeostasis (V\textsubscript{2R}) [6–8], blood pressure of the sympathetic nervous system (V\textsubscript{1aR}, V\textsubscript{2R}) [23,24]. VP is structurally similar to oxytocin (OT) and can also activate the closely related oxytocin receptor (OTR) [25]. Dysregulation of VP signaling is linked to a wide array of disorders including autism [18,26–28], cancer development [29,30], cardiovascular disorders [31,32], polycystic kidney disease [33], nephrogenic diabetes insipidus [34], and nocturia [35]. VP ligand-receptor interaction has been the subject of longstanding research and drug design efforts [28,32,36,37]. Nevertheless, structural dynamics and details of its receptor interactions remain unclear, particularly due to the lack of crystal or electron microscopy structures, and therapeutic targeting of its interactions has had only limited success to date [36,37].

VP comprises a six amino acid containing, disulfide-cyclic subunit linked to an amidated three-residue C-terminal tail. Pro\textsuperscript{7} functions as a hinge between these two subunits [38,39]. Arg\textsuperscript{8} in the three-residue tail is a primary modulator of VP-receptor (VPR) selectivity (compared to OTR) [40,41], whose spatial position is crucial for binding [41]. Similarly, Pro\textsuperscript{7} plays a role in V\textsubscript{1aR} and
2. Results

2.1. Vasopressin’s conformational sub-ensembles

In our MD trajectories (all-atom simulations, pH 7.4, 37 °C), VP sampled three well-distinguishable sub-ensembles including two in which Pro7 adopted its natural trans state. One of these is characterized by a compact three-residue tail and the other by an extended tail (Fig. 1a), which is in agreement with reported conformational switches [52]. The third sub-ensemble was observed when Pro7 adopts a cis state, in which the peptide tail also adopted an extended conformation. A compact sub-ensemble with Pro7 in a cis state was not detected (Fig. 1b). We have denoted these three observed ensembles as CTRANS, ETRANS and ECSIS indicating compacted (C) and extended (E) states of the three-residue tail as well as the cis and trans conformations of Pro7 in the index.

In the case of the compact CTRANS tail conformation, Arg8 folds transiently back towards Tyr2 and is stabilized by side-chain interactions between both residues (see Fig. 1a). In particular, the Tyr2-Arg8 hydrogen bonds appear to stabilize the compacted fold. This “back-folded” structure is distinct from the extended solvent-exposed tail conformations ETRANS (Fig. 1a). The differential structural sampling of the two trans forms constitutes a bimodal conformational space, which is reflected in the intramolecular distances between atoms Arg8(H)^—Tyr2(H). The conformational space is visualized by the distance distributions in Fig. 1b. Evidently, a bimodal distance distribution is observed. Arg8(H)^—Tyr2(H) distances r as short as 0.3 nm were detected for the compacted CTRANS fold. The distance distribution of this compact structural ensemble housing the back-folded state is centered

\[ r = 0.3 \text{ nm} \]

Virtual screening techniques are well-established in the context of in-silico drug discovery [45,47,48] and were here expanded to peptide-receptor interactions. For virtual screening in drug-receptor interactions [44,49], a library of drugs is typically docked to a receptor and compounds displaying the desirable binding properties are selected for further analysis. We replaced the library of drugs with a library of VP conformational ensembles to assess the conformational selectivity involved in VP-V1aR recognition. We used the VP-V1aR interaction as a model system, given its particular importance for regulating cardiovascular functions.

With our approach, we demonstrate how conformational selection-type events upon encounter complex formation can be assessed. In particular, we can assess in-silico which structures within the heterogeneous peptide conformational space favor complex formation. Thereby, we introduce a new approach of virtual conformational space screening at the example of a medically important target. This advancement of the virtual screening methodology enables several novel avenues for understanding peptide activities and ligand modifications in the context of SARs and drug development.

Our approach comprises two stages: First, we identified distinct sub-ensembles within the total VP structural ensemble by integrating molecular dynamics (MD) simulations and NMR spectroscopy. Then, we independently docked the identified sub-ensembles to an inactive V1aR-homology model [46] and screened the resulting complex structures for variations in binding energies and dissociation constants to identify preferentially selected peptide conformations.

V1aR preferentially selected VP conformations featuring solvent-exposed tail units, as these enabled adoption of energetically favorable complex conformations. This contrasts with two other identified sub-ensembles that feature structural restraints due to intramolecular side-chain contacts or cis-configuration of Pro7 and three-fold reduced binding energies.

Virtual screening techniques are well-established in the context of in-silico drug discovery [45,47,48] and were here expanded to peptide-receptor interactions. For virtual screening in drug-receptor interactions [44,49], a library of drugs is typically docked to a receptor and compounds displaying the desirable binding properties are selected for further analysis. We replaced the library of drugs with a library of VP conformational ensembles to assess the conformational selectivity involved in VP-V1aR recognition.

Comparable approaches by Bonvin and co-workers were already successful in generating flexible protein–protein [50] and protein-peptide [51] complexes. This was achieved either by screening conformations observed in NMR structure predictions for varying binding energies [50], or by individually docking different peptides with varying degrees of conformational freedom to a target receptor [50].

Here, we first ran an MD simulation of VP in solution to obtain the library of conformations to be docked.

In our MD trajectories (all-atom simulations, pH 7.4, 37 °C), VP sampled three well-distinguishable sub-ensembles including two in which Pro7 adopted its natural trans state. One of these is characterized by a compact three-residue tail and the other by an extended tail (Fig. 1a), which is in agreement with reported conformational switches [52]. The third sub-ensemble was observed when Pro7 adopts a cis state, in which the peptide tail also adopted an extended conformation. A compact sub-ensemble with Pro7 in a cis state was not detected (Fig. 1b). We have denoted these three observed ensembles as CTRANS, ETRANS and ECSIS indicating compacted (C) and extended (E) states of the three-residue tail as well as the cis and trans conformations of Pro7 in the index.

In the case of the compact CTRANS tail conformation, Arg8 folds transiently back towards Tyr2 and is stabilized by side-chain interactions between both residues (see Fig. 1a). In particular, the Tyr2−OH^—H—Arg8 hydrogen bonds appear to stabilize the compacted fold. This ‘back-folded’ structure is distinct from the extended solvent-exposed tail conformations ETRANS (Fig. 1a). The differential structural sampling of the two trans forms constitutes a bimodal conformational space, which is reflected in the intramolecular distances between atoms Arg8(H)^—Tyr2(H). The conformational space is visualized by the distance distributions in Fig. 1b. Evidently, a bimodal distance distribution is observed. Arg8(H)^—Tyr2(H) distances r as short as 0.3 nm were detected for the compacted CTRANS fold. The distance distribution of this compact structural ensemble housing the back-folded state is centered

\[ r = 0.3 \text{ nm} \]

Virtual screening techniques are well-established in the context of in-silico drug discovery [45,47,48] and were here expanded to peptide-receptor interactions. For virtual screening in drug-receptor interactions [44,49], a library of drugs is typically docked to a receptor and compounds displaying the desirable binding properties are selected for further analysis. We replaced the library of drugs with a library of VP conformational ensembles to assess the conformational selectivity involved in VP-V1aR recognition. We used the VP-V1aR interaction as a model system, given its particular importance for regulating cardiovascular functions.

With our approach, we demonstrate how conformational selection-type events upon encounter complex formation can be assessed. In particular, we can assess in-silico which structures within the heterogeneous peptide conformational space favor complex formation. Thereby, we introduce a new approach of virtual conformational space screening at the example of a medically important target. This advancement of the virtual screening methodology enables several novel avenues for understanding peptide activities and ligand modifications in the context of SARs and drug development.

Our approach comprises two stages: First, we identified distinct sub-ensembles within the total VP structural ensemble by integrating molecular dynamics (MD) simulations and NMR spectroscopy. Then, we independently docked the identified sub-ensembles to an inactive V1aR-homology model [46] and screened the resulting complex structures for variations in binding energies and dissociation constants to identify preferentially selected peptide conformations.

V1aR preferentially selected VP conformations featuring solvent-exposed tail units, as these enabled adoption of energetically favorable complex conformations. This contrasts with two other identified sub-ensembles that feature structural restraints due to intramolecular side-chain contacts or cis-configuration of Pro7 and three-fold reduced binding energies.

Virtual screening techniques are well-established in the context of in-silico drug discovery [45,47,48] and were here expanded to peptide-receptor interactions. For virtual screening in drug-receptor interactions [44,49], a library of drugs is typically docked to a receptor and compounds displaying the desirable binding properties are selected for further analysis. We replaced the library of drugs with a library of VP conformational ensembles to assess the conformational selectivity involved in VP-V1aR recognition. Comparable approaches by Bonvin and co-workers were already successful in generating flexible protein–protein [50] and protein-peptide [51] complexes. This was achieved either by screening conformations observed in NMR structure predictions for varying binding energies [50], or by individually docking different peptides with varying degrees of conformational freedom to a target receptor [50].

Here, we first ran an MD simulation of VP in solution to obtain the library of conformations to be docked.

In our MD trajectories (all-atom simulations, pH 7.4, 37 °C), VP sampled three well-distinguishable sub-ensembles including two in which Pro7 adopted its natural trans state. One of these is characterized by a compact three-residue tail and the other by an extended tail (Fig. 1a), which is in agreement with reported conformational switches [52]. The third sub-ensemble was observed when Pro7 adopts a cis state, in which the peptide tail also adopted an extended conformation. A compact sub-ensemble with Pro7 in a cis state was not detected (Fig. 1b). We have denoted these three observed ensembles as CTRANS, ETRANS and ECSIS indicating compacted (C) and extended (E) states of the three-residue tail as well as the cis and trans conformations of Pro7 in the index.

In the case of the compact CTRANS tail conformation, Arg8 folds transiently back towards Tyr2 and is stabilized by side-chain interactions between both residues (see Fig. 1a). In particular, the Tyr2−OH^—H—Arg8 hydrogen bonds appear to stabilize the compacted fold. This ‘back-folded’ structure is distinct from the extended solvent-exposed tail conformations ETRANS (Fig. 1a). The differential structural sampling of the two trans forms constitutes a bimodal conformational space, which is reflected in the intramolecular distances between atoms Arg8(H)^—Tyr2(H). The conformational space is visualized by the distance distributions in Fig. 1b. Evidently, a bimodal distance distribution is observed. Arg8(H)^—Tyr2(H) distances r as short as 0.3 nm were detected for the compacted CTRANS fold. The distance distribution of this compact structural ensemble housing the back-folded state is centered

\[ r = 0.3 \text{ nm} \]
at ~ 0.5 nm (Fig. 1b, left). By contrast, the extended mode that includes all other disordered states spans distances up to 2.5 nm whilst being centered at 1.9 nm (Fig. 1b, right).

When the conformation of Pro7 switches from a trans to cis state, only extended peptide tails were sampled (Fig. 1b, right panel, monomodal histogram). Here, the Arg8(HN)-Tyr5(Hε) distances span a broad dominant distribution centered at ~ 2.2 nm, consisting of species having separations ranging again from 1.2-8 nm. Fig. 1c displays the time trajectories underlying the distance distributions. It can be seen how VP in the Pro7-trans state switches between the two sub-ensembles, i.e., compact (indicated by the blue area) and extended. No such switches were observed for the Pro7-cis state.

The three different peptide tail ensembles were confirmed in three independent MD runs (Fig. 1 shows one replica; see Supporting Information for the other two replicas; note that each run contains two independent data sets for the trans- and cis-conformations, respectively. Hence, six MD trajectories were computed in total). Note that we refrained from a quantitative assessment of the MD data due to the finite length of the trajectories. Instead, we restricted our interpretation on the observation of the three different sub-ensembles, but did not quantify their relative populations or the frequencies of conformational switches.

2.2. Virtual conformational space screening

Next, we randomly selected 50 structures from the three sub-ensembles observed in the MD trajectories and docked these in silico to an established V1αR model [46]. For computation, we used VINA (Vina Is Not Autodock [53,54]); further details can be found in the Experimental section. This virtual conformational space screening approach is illustrated in Fig. 2a. From the all-atoms MD trajectories, snapshots of 50 different VP conformations were independently docked to the V1αR model. The VP structures for each of the three sub-ensembles (C TRANS, E TRANS and E CIS) that led to the lowest dissociation constants are depicted in Fig. 2b and the associated ligand-receptor complex structures in Fig. 2c.

It was interesting to observe how residues Tyr2 and Phe3 interacted with transmembrane helices (TMH) 3 and 4 in all cases to provide optimal complex stability (in agreement with published results [41]). In contrast, the position of the three-residue tail varied for the three docked cases C TRANS, E TRANS and E CIS. The pre-formed tail structures were conserved upon docking to the receptor which led to different complex conformations. Most prominently, tail residue Arg4 interacted with TMH 6 in the E TRANS, but with TMH 5 for the C TRANS and E CIS states, while tail residue Gly9 interacted with TMH 6 in the E TRANS and C TRANS states, but with TMH 4 in the E CIS state. These findings are in partial agreement with published structures of the VP-V1αR complex. These displayed similar interaction patterns for the three-residue tail with TMH 4 [41,55]. Yet, the interaction with TMH 6 was not reported.

For statistical analysis, each docking experiment for the 50 selected VP conformations was repeated 25 times yielding 1250 VP-V1αR complexes per sub-ensemble. Each computed complex structure was analyzed with respect to binding energies and dissociation constants K D. Fig. 2d displays box plots for the three sub-ensembles C TRANS, E TRANS and E CIS, calculated in each case from the top five ligand-receptor complex structures with respect to binding energies. The same analysis was performed for three independent runs. In each run, the E TRANS state led to significantly lower dissociation constants compared to C TRANS and E CIS. The p-values for comparing the compacted and extended conformations the three runs were 1.0 × 10⁻³, 1.6 × 10⁻³ and 1.9 × 10⁻¹. The full list of computed values is in the Supporting Information (Table S1). Our findings were further confirmed by comparison of the dissociation constants calculated for the complex structure with the best VINA score out of the 1250 structures (Fig. 2e). E TRANS led in all runs to two- to three-fold reduced dissociation constants. Note that several structures with comparably low dissociation constants have been computed (see Table S1). Since only results with the five highest VINA scores were used for computation of the box plots in Fig. 2d, the bottom edges converge to the values shown in Fig. 2e.

2.3. NMR validation of the VP structure: The heterogeneous conformational space of the VP Pro7-trans form

To validate the MD-based results, we experimentally probed VP’s conformational space by means of solution-state NMR spectroscopy. Evidence for the tri-modal sampling space of the three-residue tail was observed in 1H–1H NOESY and 1H–1H TOCSY experiments. An overlay of TOCSY (blue) and NOESY (red-green) NMR spectra of VP in phosphate buffered solution at pH 6.5 is presented in Fig. 3a. The resonances of Gly3 and Arg2 are both split into two clear signals along the direct dimension, indicating the presence of the cis and trans Pro7 isoforms (further confirmation by repeated annealing is presented in the Supporting Information). Additionally, three features are notable in the NOESY data: (i) Arg2(Hε)-Gly3(Hδ) cross-peaks were observed for the Pro7-trans state, but not for the cis state, (ii) Arg2(Hε)-Tyr5(Hε) cross-peaks were observed (Fig. 3b; note that these NOEs contacts stem from different atoms than the H-bond described in Fig. 1); as the Arg2(Hε) could not be identified by NMR., and, most importantly, (iii) the Arg2(Hδ)-Arg5(Hδ) and the Arg2(Hε)-Arg5(Hδ) cross-peaks had a negative amplitude for the Pro7-cis and a positive one for the Pro7-trans state (with respect to positively phased diagonal peaks; green signals represent fast motions and red restricted motions; Fig. 3c).

The presence of these features confirmed the conformational sampling of the MD simulations for the acyclic Pro7-Arg5-Gly9 tail. In particular, the positive amplitudes for the Arg5(Hδ)-Arg5(Hδ) and the Arg5(Hε)-Arg5(Hε) NOE cross-peaks for the Pro7-trans state indicate slowed conformational dynamics of the three-residue tail.

Fig. 2. a) Sketch of the virtual conformational space screening approach. First, an MD simulations generated different sub-ensembles and conformational snapshots. Then, randomly selected structures were fed into independent docking experiments and later associated with a particular VP state. Note that the shown VP structures do not represent the conformations chosen for analysis in panels (b) to (e), but serve only as visualization of the virtual conformational screening method. b) Structures of VP in its E TRANS (center) and E CIS (right) state. The displayed structures are VP-V1αR complexes with the lowest dissociation constants in our simulations. c) VP-V1αR complexes computed for the three structures shown in panel (b); E TRANS (left), C TRANS (center) and E CIS (right). The transmembrane helix (TMH) numbering is indicated. Note how VP residue Arg2 varied its position (between TMHs 4 to 6), while Tyr5 and Phe3 always bound to TMH 3 and 4. d) Box plots of dissociation constants computed for the E TRANS (left), C TRANS (center) and E CIS (right) sub-ensembles for three independent MD runs from the structure with the best VINA scores. The K D for the E TRANS sub-ensemble were always lower than those of the other two sub-ensembles. Red crosses indicate outliers, the red bars mean values, bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. e) Representation of K D for the complexes with the best scores in our docking experiments, with E TRANS having significantly reduced dissociation constants. Note that these values approach the bottom edges of the boxes in panel d (see the main text for details). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
By contrast, in the Pro\(^7\)-cis state, only negative cross-peaks were observed indicating faster side-chain dynamics. This validated the heterogeneous conformational space of the VP three-residue tail, as only transient intramolecular attraction between the tail and the macrocycle residues could account for these observations [52]. Given the observation of Arg\(^8\)(H\(^N\))-Tyr\(^2\)(H\(^\alpha\)) cross-peaks, attractive interaction between tail residue Arg\(^8\) and the Tyr\(^2\) aromatic side-chain appear intuitive as an underlying force, which aligned well with the structures computed for the C\(\text{TRANS}\) case.

We conclude that VP, when Pro\(^7\) adopts the trans state, indeed populates a bimodal conformational space due to transient side-chain interactions between Tyr\(^2\) and Arg\(^8\) that slows down conformational sampling, i.e., the intramolecular dynamics. In the Pro\(^7\)-cis state, no indications of a conformationally restrained sub-ensemble were observed, and hence no compacted state could be inferred, in line with the MD results. Besides, the observation of slow conformational dynamics for the trans-state indicates that the C\(\text{TRANS}\) forms dominate the conformational ensemble when Pro\(^7\) adopts the trans-state. Indeed, a predominance of extended conformations likely would result in fast backbone and side-chain dynamics and a similar cross-peak sign as observed for the E\(\text{cis}\) structural ensemble.

Note that a line shape analysis supports this conclusion. The trans-state leads to a broader linewidth compared to the cis-state (Fig. 3c and S5-S7 in the Supporting Information, the trans-state G\(^9\) peak even overlaps with the cis-state one). This indicates, in agreement with the above interpretation, an exchange-based line broadening as the trans-state exchanges between two conformations. However, the cis-state only samples extended forms such that no exchange broadening is observed.

It has been suggested that both the cis and trans conformations of VP are populated under physiological conditions, owing to the similarity in energy of their respective proline backbone bond configurations [39,56,57]. At the same time, the energy barrier for bond rotation is sufficiently high to permit observation of the separate resonances for both isomers on the NMR time scale [58]. Indeed, previous NMR investigations of VP structure observed spectroscopic fingerprints of two isomers, observing Pro\(^7\)-cis populations in the range of 5–9% [56,38] under near-physiological conditions. Here, under our conditions (pH 6.5, 25 °C), we were able to detect the presence both states simultaneously. To this end, we used the almost pure cis-form as starting material and obtained ~60% trans populations (as judged from the NMR peak intensities) after annealing at 60 °C for 8 h.

### 3. Discussion

V\(_{1\alpha}\)R is the main receptor in mediating these functions [59] and it is thus not surprising that significant efforts have been made to develop selective V\(_{1\alpha}\)R agonists and antagonists for therapeutic applications as well as to study this signaling system [60,61].

Targeting V\(_{1\alpha}\)R has been a long-standing research challenge [28,37,46,62,63] mainly due to the selectivity problems to its closely-related receptor subtypes, namely V\(_{2}\)R, V\(_{3}\)R and OTR. Our findings might therefore be of interest to the medicinal chemistry community for the development of more potent and selective V\(_{1\alpha}\)R ligands. In particular, one could envisage to implement unnatural amino acids that shift the C\(\text{TRANS}\)/E\(\text{TRANS}\) population equilibrium to improve receptor affinity and potentially also receptor subtype selectivity. Our simulations indicate that the Tyr\(^2\)-OH--–NH-Arg\(^8\) hydrogen bond particularly stabilizes the C\(\text{TRANS}\) state. Hence, modification of either the Tyr\(^2\) or the Arg\(^8\) residue might foster an overpopulation of the better binding E\(\text{TRANS}\) state, e.g., by introducing a methylated Tyr\(^2\) modification that lacks the possibility to form the hydrogen bond in question. Alternatively, the binding affinity of VP to V\(_{1\alpha}\)R could be modulated by directly manipulating the cis–trans equilibrium of the Pro\(^7\) residue [64,65]. Such strategic modifications could deliver important potency and selectivity improvements for V\(_{1\alpha}\)R binding, which is critical for therapeutic lead development.

Concerning the computed complex structures, we found that the dissociation constant of the VP-V\(_{1\alpha}\)R complex depends on the spatial conformation of the VP three-residue tail. The lower dissociation constant for E\(\text{TRANS}\) indicates a preferential binding of the corresponding structural sub-ensemble to the receptor. From
Fig. 2c we deduce that the conformation with an extended peptide tail enables simultaneous interactions of VP residue Arg⁸ with TMH 6, accompanied simultaneously by interactions aromatic side-chains of Tyr² and Phe⁴ with TMHs 2 and 4, respectively. This complex configuration led to the highest binding energies in our simulations but was not observed in the E_{cis} or E_{trans} states, suggesting that this unique configuration drives the observed conformational selectivity. This is supported by other studies stating that the VP ligand-receptor complex is characterized by an intricate network of hydrogen bond interactions across several residues, rather than by a few well-defined points of contact [66]. The ligand-receptor interactions in the complex consist primarily of contacts between the residues of the cyclic part of VP and TMHs 3 and 4 and the extracellular loops of the receptor [55,66]. At the same time, the C-terminal tail modulates binding affinities via a few intermolecular contacts [66]. Indeed, SAR studies of VP revealed that modification or replacement of Pro⁷ in VP can affect V₁a/V₂ receptor selectivity [67,68].

It should be noted that the herein computed differences in dissociation constants between the compacted and extended VP conformations likely do not suffice to lead to a ‘pure’ conformational selection-type binding event. Instead, a more complex binding process that features aspects of structural selectivity appears to be more probable. Moreover, due to the nature of virtual docking experiments with limited receptor flexibility, the computed dissociation constants correspond to conformations found upon ligand-receptor encounter. In other words, the E_{trans} state is preferentially selected by V₁aR for encounter complex formation as the likelihood of dissociation is significantly reduced in comparison to the E_{cis} and C_{cis} VP states. However, subsequent conformational sampling and structural adaption in the complex are not excluded by the presented methodology. In contrast, it is not unlikely that the selectivity towards a particular encounter complex structure can guide the VP-V₁aR system towards a particular final complex structure.

VP has received substantial attention from both, the structural biology [36,41,55] and medicinal chemistry communities [28,69,70], and V₁aR remains a drug target of interest. However, crystallization and electron microscopy efforts so far have failed to provide a high-resolution structure of this receptor. With longer MD trajectories, higher computing power, more refined V₁aR homology models, and high-sensitivity NMR becoming more accessible, deeper insights into the conformational characteristics of VP and its receptor interactions can be provided. We capitalized on these developments in this study and adapted a well-established in-silico methodology for screening receptor interactions of potential drug candidates to the screening of solution conformations for favorable binding properties. In classical virtual screening experiments, the rational selection of the ligand set often constitutes a bottleneck, but we could overcome this by confirming the selected conformations experimentally by NMR spectroscopy.

4. Conclusions

We developed a ‘virtual conformational space screening’ that provided new insights into the interactions of VP with V₁aR. We could establish that the binding event has different energetic preferences based on the sampled and experimentally verified conformations of the VP three-residue tail. In particular, the extended conformations of the Pro²-trans configuration (E_{trans}) led to a reduced dissociation constant and favorable binding energies. Our results highlight the key role of the three-residue ‘tail’ in determining VP conformational selectivity, providing missing atomic-level detail to the current understanding of VP-V₁aR interaction – an aspect that opens novel research avenues for understanding the functionality of the evolutionarily selected conformational properties of VP, as well as guidance for ligand design strategies to provide more potent and selective VP analogues. Our VCSS is fast, easy to implement, applicable to other peptide-receptor systems, and data interpretation is straightforward. We expect this methodological advance to be interesting for a spectrum of chemists and biologists as it enables the elucidation of peptide-receptor recognition events at the atomic level.

5. Experimental

VP was obtained from Biosynth Carbosynth (Compton, United Kingdom).

5.1. NMR spectroscopy

For NMR spectroscopy VP was dissolved at 3 mg/mL in PBS buffer at pH 6.0 (90% H₂O and 10% D₂O; 25 mM Na₂HPO₄, 25 mM KH₂PO₄, 25 mM NaCl). NMR spectra were recorded on a 600 MHz Bruker NEO spectrometer equipped with a Prodigy TCI probe head. All spectra were acquired at 25 °C. TOCSY and NOESY data were recorded using the Bruker ‘dipsi2ggph19’ and ‘noesyfpgppphs19’ pulse sequences for TopSpin 4. For annealing, the samples were heated to a maximum of 60 °C for 8 h. The high temperatures were necessary as the cis–trans conversion features high energy barriers and is rather slow. All TOCSY spectra were recorded with a spectral width of 8196.7 Hz in both dimensions and 32 scans. Mixing time was 150 ms. QUADRATURE detection was done using States-TIPPI. All NOESY spectra were measured with width of 9615.3 Hz in the F2 dimension and 7202.1 Hz in the F1 dimension. We recorded 32 scans. The mixing time was 300 ms. QUADRATURE detection was employed again using States-TIPPI sampling schemes.

Spectral processing was achieved using TopSpin, NMRPipe [71], and Sparky [72]. All data were zero filled to twice the original number of data points and apodized using a 60° shifted sine bell function prior to Fourier transformation. This was followed by a polynomial baseline correction in the frequency space.

Line shape analysis were conducted using home-written scripts for the MATLAB software package employing the ‘fitnlorentian.m’ function.

5.2. MD simulations

We performed all-atoms MD simulations of VP, beginning from either Pro²-cis- or -trans conformations. The published Pro²-trans VP structure was used as starting model [73]. To obtain the Pro²-cis form the N–C bond was switched accordingly. This was followed in both cases by energy minimization and simulated annealing in explicit solvent (1% NaCl in water at pH 7.4). Finally, trajectories were recorded at 37 °C at 2 fs time steps.

MD-simulations were performed using the YASARA software-package [74,75]. The AMBER03 force field was employed with periodic boundary conditions [76]. Non-bonded interactions were cut off at 1.05 nm Long-range Coulombic interactions were treated by a smoothed particle-mesh Ewald method [77,78]. Non-canonic amino acids were built using YASARA and semi-quantum-mechanically parameterized (YAPAC-AM1). MD trajectories of > 120 ns length were accumulated for the two systems. In total, six trajectories were computed, i.e., for both states (cis and trans) three trajectories were computed. Intermolecular forces were recalculated at every second simulation sub-step. Temperature rescaling was employed with a set-temperature of 37 °C. The box dimensions (cubic of 37 Å side length) were controlled to yield a solvent pressure of 1 bar. Snapshots of the simulations were taken every 10,000 fs.
5.3. Receptor docking

Insights into ligand-receptor interactions were generated using VINA [53] as implemented in YASARA. We used a recently reported homology model of V1aR [46]. 25 structures were generated for each docked structure. Side-chains flexibility was enabled upon docking the ligand structures. Dissociation constants were calculated from the binding energies $\Delta G_{\text{binding}}$ following the Autodock method and conventions:

$$K_{\text{binding}} = 1/K_D,$$

$$\ln K_{\text{binding}} = -\ln K_D,$$

$$\Delta G_{\text{binding}} = -RT \ln K_{\text{binding}}.$$

The binding energy $\Delta G_{\text{binding}}$ was calculated using the ‘BindEnergy’ macro implemented in YASARA, i.e., by determining the energy at infinite distance (between the object and the rest of the soup, i.e., the unbound state) and then subtracting the energy of the soup (the bound state). The more positive the binding energy, the more favorable the interaction. It should be noted that such determined energies are representing approximations that should only be compared among each other. They should not be understood as independent absolute measures of binding affinities. For each of the MD runs, the three sub-ensembles were identified, and the respective docking experiments were performed. This led to a total of nine docking experiments. The initial VP structure for docking to V1aR were chosen randomly from the respective conformational sub-ensembles using the MATLAB random number generator. Box plots (Fig. 2) were calculated using the ‘boxplot’ function implemented in the MATLAB software package.

CRediT authorship contribution statement

Kateryna Che: Investigation, Methodology, Visualization. Markus Muttenzhaler: Conceptualization, Funding Acquisition. Writing – review & editing. Dennis Kurzbach: Conceptualization, Funding Acquisition, Writing – original draft.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors acknowledge support by the NMR core facility of the Faculty of Chemistry, University of Vienna. The authors thank Mr. Thomas Kremsmayr for his support. The project leading to this application received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreements 801936 and 714366) and by the Australian Research Council (DE150100784, DP190101667).

Data availability

All data are available under DOI 10.5281/zenodo.5592280.

Author contributions

KC and DK performed NMR and MD studies. MM and DK conceived the study. DK wrote the manuscript with the help of all authors. All authors approved the final manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2021.10.024.

References

[1] Thibonnier M et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998;449:251–76.
[2] Morel A, O’Carroll A-M, Brownstein MJ, Lolaft SJ. Molecular cloning and expression of a rat V1b vasopressin receptor. J. Endocrinology 1992:356 (6369):523–6.
[3] Sugimoto T et al. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J. Biol Chem 1994;269:27088–92.
[4] Binshaurer M, Sehohl A, Gilbert S, Ishido M, Barberis C, Antaramian A et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992;357(6376):333–5.
[5] Lollaj SJ, O’Carroll A-M, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992;357(6376):336–9.
[6] Robertson GL, Shenton RL, Ather S. The osmoregulation of vasopressin. Kidney Int 1976;10(1):25–37.
[7] Boone M, Deen PMT. Physiological and pathophysiological of the vasopressin-regulated renal water reabsorption. Pflugers Arch 2008;456:1005–24.
[8] Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and treatment of liver cirrhosis. J. Hepatol. 2012;56(1):1–10.
[9] Smith PM, Ferguson AV. Vasopressin acts in the subfornical organ to decrease blood pressure. Neuroendocrinology 1997;66(2):130–5.
[10] Thurston CL, Cullhane ES, Suberg SN, Carstens E, Watkins LR. Antinociception vs motor effects of intrathecal vasopressin as measured by four pain tests. Brain Res 1988;463:1–11.
[11] Kordover JH, Bodnar RJ. Vasopressin analogs: specificity of action and non-opioid effects. Peptides 1984;5(4):747–56.
[12] Weingartner H, Gold P, Ballenger JC, Smallberg SA, Summers R, Rubinov DR, et al. Effects of vasopressin on human memory functions. Science 1981;211 (4482):601–3.
[13] Abramova O, Zorkina Y, Ushakova V, Zubkov E, Morozova A, Chekhonin V. The role of oxytocin and vasopressin dysfunction in cognitive impairment and mental disorders. Neuropeptides 2020;83:102079.
[14] Heinrichs M, van Dawans B, Domes G, Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 2009;30(4):548–57.
[15] Albers HE. The regulation of social recognition, social communication and aggression: Vasopressin in the social behavior neural network. Horm Behav 2012;61(3):283–92.
[16] Insel TR, O’Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection? Biol Psychiatry 1999;45:145–57.
[17] Dumas KM, Veenvensa AH. Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior. Front Neuroendocrinol 2016;40:1–23.
[18] Gibbs DM. Vasopressin and oxytocin: hypothalamic modulators of the stress response. A review. Psychoneuroendocrinology 1986;11(2):131–9.
[19] Stevenson EL, Caldwell HK. The vasopressin 1b receptor and the neural regulation of social behavior. Horm Behav 2012;61:277–82.
[20] Senn M, Maier PM, Langhans W. ACTH, cortisol and glucose responses after administration of vasopressin in cattle and sheep. J Comp Physiol B 1995;164:570–7.
[21] Hems DA, Whitton PD. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem J 1973;136:705–9.
[22] Kvetansky R. Regulation of the sympathetic nervous system by circulating vasopressin. In: Porter JC, Jezóvá D, editors. Circulating regulatory factors and neuroendocrine function. US: Springer; 1990. p. 113–34.
[23] Hassel EM et al. Area postrema and sympathetic nervous system effects of vasopressin and angiotensin II. Clin Exp Pharmacol Physiol 2000:27:432–6.
[24] Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H. Structure and expression of a human oxytocin receptor. Nature 1992;356 (6369):526–9.
[25] Oztan O, Garner JP, Constantino JN, Parker KJ. Neonatal CSF vasopressin concentration predicts later medical record diagnoses of autism spectrum disorder. Proc Natl Acad Sci 2020;117:1069–13.
[26] Carson DS, Garner JP, Hyde SA, Libove RA, Berquist SW, Hornbeak KB et al. Arginine vasopressin is a blood-based biomarker of social functioning in children with autism. PLoS ONE 2015;10(7):e0132228.
[27] Schnider P et al. Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder. J Med Chem 2020;63:1511–25.
[28] Péqueux C et al. Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer 2004;11:871–85.
[29] Taylor AH et al. Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 1990;50:7882–6.
Yedvabny E, Nerenberg PS, So C, Head-Gordon T. Disordered structural

Saleh N et al. A Three-site mechanism for agonist/antagonist selective binding

Mateos B et al. The ambivalent role of proline residues in an intrinsically

Doupnik CA, Parra KC, Guida WC. A computational design approach for virtual

Dekan Z et al. Nature-inspired dimerization as a strategy to modulate

Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin

Hagiwara Y et al. Molecular modeling of vasopressin receptor and

Larive CK, Guerra L, Rabenstein DL. Cis/trans conformational equilibrium

Forli S et al. Computational protein–ligand docking and virtual drug screening

Wang X, Wu Y, Ward CJ, Torres VE. Vasopressin directly

Leffler AE et al. Discovery of peptide ligands through docking and virtual

Kurkcuoglu Z, Bonvin AMJJ. Pre- and post-docking sampling of conformational

Essmann U et al. A smooth particle mesh Ewald method. J Chem Phys

Natsume O. A Clinical investigation of nocturnal polyuria in patients with

McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol

Andrés M, Trueba M, Guillon G. Pharmacological characterization of F-180: a

Doshi U, Hamelberg D. Reoptimization of the AMBER force field parameters for

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of
docking with a new scoring function, efficient optimization and
mulithreading. J Comput Chem 2010;31:455–61.

Jaghoori MM, Bleijeveld B, Obarriagia 3D. 1001 Ways to run AutoDock Vina
for virtual screening. J Comput Aided Mol Des 2016;30:237–49.

Mouilla B et al. The binding site of neuropeptide vasopressin V1α receptor: evidence for a major localization within transmembrane regions. J Biol Chem 1995;270:25771–7.

Lanive CR, Guerra L, Rabenstein DL. Cis/trans conformational equilibrium across the cysteine6–proline peptide bond of oxytocin, arginine vasopressin, and lysine vasopressin. J Am Chem Soc 1992;114:7331–7.

Lanive CR, Rabenstein DL. Dynamics of cis/trans isomerization of the cysteine6–proline peptide bonds of oxytocin and arginine-vasopressin in aqueous and methanol solutions. J Am Chem Soc 1993;115:2833–6.

Dyson HJ, Rance M, Houghten RA, Lerner RA, Wright PE. Folding of immunogenic peptide fragments of proteins in water solution: I. Sequence requirements for the formation of a reverse turn. J Mol Biol 1988;201:161–200.

Koshimizu T et al. Vasopressin V1a and V1b receptors: from molecules to
physiological systems. Physiol Rev 2012;92:1813–64.

Manning M, et al. Peptide and non-peptide agonists and antagonists for the
vasopressin and oxytocin V1α, V1b, V2 and OT receptors: research tools and
potential therapeutic agents. In: Progress in brain research, Elsevier, 2008, vol. 170, p. 473–512.

Manning M et al. Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics. J Neuroendocrinol 2012;24:609–28.

Park SE et al. Luteolin, a Potent Human Monoamine Oxidase-A Inhibitor and Dopamine D 3 and Vasopressin V 1α Receptor Antagonist. J Agric Food Chem 2012;60:9505–12.

K. Che, M. Muttenthaler and D. Kurzbach Computational and Structural Biotechnology Journal 19 (2021) 5826–5833

Petersen HG. Accuracy and efficiency of the particle mesh Ewald method. J Phys Condens Matter 1995;7:3529–45.

Pandit P et al. A new technique for adaptive biasing of protein structures using NMR spectroscopy. J Phys Chem B 2002;106:3171–8.

Trellet M, Melquiond ASJ, Bonvin AMJJ, Keskin O. A unified conformational
ensembles of vasopressin and oxytocin and their mutants. J Mol Biol 1997;266:769–809.

Simonovics E, Rodziewicz-Motowidlo S. Conformational studies of vasopressin and mesotocin using NMR spectroscopy and molecular modelling methods. Part 1: studies in water. J Pept Sci 2008;14:76–84.

Yedvabny E, Nerenberg PS, So C, Head-Gordon T. Disordered structural
ensembles of vasopressin and oxytocin and their mutants. J Phys Chem B 2015;119:896–905.

Saleh N et al. A Three-site mechanism for agonist/antagonist selective binding to vasopressin receptors. Angew Chem Int Ed 2016;55:8006–12.

Sliusar MJ, Gielo-Perczak A, Sliusar S, Cieplakowski J. Analysis of interactions responsible for vasopressin binding to human neurohypophysial hormone receptors–molecular dynamics study of the activated receptor–vasopressin–Co system. J Pept Sci 2006;12:180–9.

Schirmer RE, Noggle JH, Davis JP, Hart PA. Determination of molecular geometry by quantitative application of the nuclear Overhauser effect. J Am Chem Soc 1970;92:3266–73.

Haensele E et al. Can simulations and modeling decipher NMR data for conformational equilibria? Arginine-vasopressin. J Chem Inf Model 2016;36:1798–807.

McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007;11(5):494–502.

Doupnik CA, Parra KC, Guida WC. A computational design approach for virtual
screening of peptide interactions across K + channel families. Comput Struct Biotechnol J 2015;13:85–94.

Di Giglio MG et al. Development of a human vasopressin V 1α-receptor antagonist from an evolutionary-related insect neuropeptide. Sci Rep 2017;7:41002.

Leffler AE et al. Discovery of peptide ligands through docking and virtual
screening at nicotinic acetylcholine receptor homology models. Proc Natl Acad Sci USA 2017;114:61810–9.

Damjanovic J, Miao J, Huang H, Lin Y-S. Elucidating solution structures of cyclic peptides using molecular dynamics simulations. Chem Rev 2021;121:2292–324.

Forli S et al. Computational protein–ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 2016;11:905–19.

Kuruczuglu Z, Bonvin AMJJ. Pre- and post-docking sampling of conformational changes using ClustENM and HADDOCK for protein–protein and protein–DNA structures. Proteins Struct Funct Bioinforma 2020;88:292–306.

Trellet M, Melquiond ASJ, Bonvin AMJJ, Keskin O. A unified conformational
ensembles of vasopressin and oxytocin and their mutants. J Mol Biol 1997;266:769–809.

Haensele E, Banting L, Whittle DC, Clark T. Conformation and dynamics of 8-Arg-vasopressin in solution. J Mol Model 2014;20:2485.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of
docking with a new scoring function, efficient optimization and
mulithreading. J Comput Chem 2010;31:455–61.

Jaghoori MM, Bleijeveld B, Obarriagia 3D. 1001 Ways to run AutoDock Vina
for virtual screening. J Comput Aided Mol Des 2016;30:237–49.